By Mill Chart
Last update: Jun 9, 2025
GENMAB A/S -SP ADR (NASDAQ:GMAB) stands out as a compelling pick for investors seeking growth at a reasonable price (GARP). The biotechnology company, known for its innovative antibody therapies, meets key criteria outlined in Peter Lynch’s investment strategy, combining solid earnings growth, strong profitability, and an attractive valuation.
GMAB’s fundamental report highlights its strengths in profitability and valuation, though revenue growth has been uneven. The company’s high margins (95.9% gross margin, 33.5% operating margin) and efficient capital allocation make it a standout in its industry.
Our Peter Lynch Strategy screener identifies more stocks that align with these principles and is updated regularly.
This is not investing advice. The observations here are based on current data, but investors should conduct their own research before making decisions.
22.2
+0.39 (+1.79%)
Find more stocks in the Stock Screener
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.
GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities.
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.